Ovarian Cancer Recurrent Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Ovarian Cancer Recurrent clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Ovarian CancerOvarian Cancer Recurrent
Compugen Ltd60 enrolled28 locationsNCT06888921
Recruiting
Phase 1Phase 2

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Ovarian Cancer Recurrent
Merck Sharp & Dohme LLC280 enrolled16 locationsNCT06843447
Recruiting
Phase 1

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Ovarian CancerPlatinum Resistant Ovarian CancerOvarian Cancer Recurrent
Outpace Bio, Inc.30 enrolled4 locationsNCT07030907
Recruiting

A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB

Ovarian Cancer RecurrentEndometrial Cancer RecurrentCervical Cancer Recurrent
Sun Yat-sen University200 enrolled2 locationsNCT06781151
Recruiting
Phase 2

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Ovarian Cancer Recurrent
InxMed (Shanghai) Co., Ltd.168 enrolled1 locationNCT06014528
Recruiting
Phase 2

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Ovarian Cancer Recurrent
Institute of Cancer Research, United Kingdom42 enrolled5 locationsNCT05990192
Recruiting
Phase 2Phase 3

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Ovarian Cancer Recurrent
Obstetrics & Gynecology Hospital of Fudan University296 enrolled1 locationNCT06791460
Recruiting
Early Phase 1

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Ovarian Cancer Recurrent
Second Xiangya Hospital of Central South University5 enrolled1 locationNCT06660511
Recruiting
Phase 2

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Primary Peritoneal CarcinomaFallopian Tube CancerOvarian Cancer Recurrent
Shanghai Gynecologic Oncology Group167 enrolled5 locationsNCT03983226